PATENT CLAIM ANALYSIS

Application Number: 16327850
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to a pharmaceutical composition for treating macular degeneration, and more particularly to a pharmaceutical composition for treating macular degeneration, which comprises an inhibitor of mTOR gene expression. The pharmaceutical composition according to the present invention can effectively treat age-related macular degeneration, a representative retinal disease that causes blindness in adults.

Claim (Index 1):
A method for treating macular degeneration, the method comprising administering to a patient an siRNA represented by the nucleotide sequence of SEQ ID NO: 1.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 99.0
- Lexical Diversity: 1.51282
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15058938', '15602096', '16160840', '14746221', '16341075']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7657094990433714
- 35 USC 102 Novelty (BERT): 0.5132541788034491
- Combined Prediction Score: 0.7404639670193792
- Mean Citation Score: 273.272424
- Max Citation Score: 280.28107
- Similarity Product: 182.72894335866928

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test